PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Sebastian Grosicki,
Su-Peng Yeh,
Shang-Yi Huang,
Ja Min Byun,
Christine Dirienzo,
Andrea Viqueira
Affiliations
Sebastian Grosicki
1 Medical University of Silesia, Department of Hematology and Cancer Prevention
Su-Peng Yeh
2 China Medical University Hospital, Taichung, Taiwan
Shang-Yi Huang
3 Taiwan University Hospital, Taipei, Taiwan
Ja Min Byun
4 Seoul National University Hospital, Seoul, Korea, Rep. of South
